Publications by authors named "F Mazingue"

Claim this Profile
R
Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study.
Nizar Mahlaoui, Fanny Fouyssac, Françoise Mazingue, Coralie Mallebranche, Malika Barthez-Toullec

Front Pediatr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Socio-economic outcomes among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: Results of the 58LAE study.
Melissa Barbati, Michal Kicinski, Stefan Suciu, Françoise Mazingue, Els Vandecruys

Eur J Cancer Care (Engl)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951.
N Sirvent, S Suciu, B De Moerloose, A Ferster, F Mazingue

Arch Pediatr· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients.
Marie-Louise Frémond, Alice Hadchouel, Laureline Berteloot, Isabelle Melki, Violaine Bresson, Françoise Mazingue

J Allergy Clin Immunol Pract· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
Caroline Piette, Stefan Suciu, Yves Bertrand, Anne Uyttebroeck, Els Vandecruys, Françoise Mazingue

Br J Haematol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis